论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
诺模图可预测乳腺癌患者的总体生存率并指导中国的术后辅助化疗
Authors Wang X, Feng Z, Huang Y, Li H, Cui P, Wang D, Dai H, Song F, Zheng H, Wang P, Cao X, Gu L, Zhang J, Song F, Chen K
Received 9 May 2019
Accepted for publication 12 October 2019
Published 28 November 2019 Volume 2019:11 Pages 10029—10039
DOI https://doi.org/10.2147/CMAR.S215000
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Melinda Thomas
Peer reviewer comments 3
Editor who approved publication: Professor Rudolph Navari
Purpose: We aim to construct a nomogram to predict breast cancer survival and guide postoperative adjuvant chemotherapy in China.
Patients and methods: A total of 5,504 breast cancer patients from the Tianjin Breast Cancer Cases Cohort were included. Multivariable Cox regression was used to investigate the factors associated with overall survival (OS) and a nomogram was constructed based on these prognostic factors. The nomogram was internal and external validated and the performance was evaluated by area under the curve (AUC) and calibration curve. The partial score was also constructed and stratified them into low, moderate and high-risk subgroups for death according to the tripartite grouping method. Multivariate Cox regression analysis and the propensity score matching method were respectively used to test the association between adjuvant chemotherapy and OS in different risk subgroups.
Results: Age, diameter, histological differentiation, lymph node metastasis, estrogen, and progesterone receptor were incorporated into the nomogram and validation results showed this nomogram was well-calibrated to predict the 3-year [AUC =74.1%; 95% confidence interval (CI): 70.1–78.0%] and 5-year overall survival [AUC =72.3%; 95% CI: 69.6–75.1%]. Adjuvant chemotherapy was negatively associated with death in high risk subgroup [Hazard Ratio (HR) = 0.54; 95% CI: 0.37–0.77; P <0.001]. However, no significant association were found in groups with low (HR=1.47; 95% CI: 0.52–4.19; P =0.47) and moderate risk (HR=0.78; 95% CI: 0.42–1.48; P =0.45). The 1:1 PSM generated 822 pairs of well-matched patients and Kaplan-Meier showed the high-risk patients could benefit from chemotherapy, whereas low risk and moderate risk subjects did not appear to benefit from chemotherapy.
Conclusion: Not all of the breast cancer patients benefit equally from chemotherapy. The nomogram could be used to evaluate the overall survival of breast cancer patients and predict the magnitude of benefit and guide adjuvant chemotherapy for breast cancer patients after surgery.
Keywords: breast cancer, prognostic prediction, cohort study, adjuvant chemotherapy
